OmniAb, Inc.
NASDAQ•OABI
CEO: Mr. Matthew W. Foehr
Sector: Healthcare
Industry: Biotechnology
Listing Date: 2021-09-30
OmniAb, Inc., a biotechnology company, engages in the discovery and provision of therapeutic antibody discovery technologies in the United States. The company's technology platform creates and screens diverse antibody repertoires and identify optimal antibodies for partners' drug development efforts. Its OmniAb platform is the biological intelligence of proprietary transgenic animals, including OmniRat, OmniChicken, and OmniMouse that have been genetically modified to generate antibodies with human sequences to facilitate development of human therapeutic candidates. The company's OmniFlic, a bispecific rat, and OmniClic, a bispecific chicken, designed for discovery of bispecific antibody applications; OmniTaur, which provides unique structural characteristics of cow antibodies for complex targets; and OmniDeep, a suite of in silico, an AI and machine learning tools for therapeutic discovery and optimization through various technologies and capabilities. OmniAb, Inc. was founded in 2012 and is headquartered in Emeryville, California.
Contact Information
Market Cap
$207.15M
P/E (TTM)
-3.6
17.6
Dividend Yield
--
52W High
$3.10
52W Low
$1.22
52W Range
Rank46Top 59.5%
3.5
F-Score
Modified Piotroski Analysis
Based on 6-year fundamentals
Weak • 3.5 / 9 points
Scoring Range (0-9)
8-9: Excellent Value
6-7: Strong Fundamentals
4-5: Average Quality
0-3: Weak Performance
Data Period: 2020-2025
Financial Dashboard
Q4 2025 Data
Revenue
$8.38M+0.00%
4-Quarter Trend
EPS
-$0.11+0.00%
4-Quarter Trend
FCF
-$5.68M+0.00%
4-Quarter Trend
2025 Annual Earnings Highlights
Key Highlights
Active Partner Growth 107 active partners in 2025, up from 91 in 2024, demonstrating strong platform adoption and market penetration across the industry.
Active Program Expansion 407 active programs in 2025, up from 363 in 2024, reflecting increased usage of technology platform by partners for drug development.
xPloration Revenue Launch xPloration revenue reached 754K USD in 2025, driven by the launch of the xPloration Partner Access Program and related instrument sales.
Royalty Revenue Increase Royalty revenue reached 878K USD in 2025, up 52% from 576K USD in 2024, driven by higher net sales from partners.
Risk Factors
Total Revenue Decline Total revenue 18.7M USD in 2025, down 29% from 26.4M USD in 2024, primarily due to lower license and milestone payments.
Net Loss Increase Net loss 64.8M USD in 2025, up from 62.0M USD in 2024, reflecting continued investment in research and development activities.
Partner Concentration Risk Three partners accounted for 37% of revenue in 2025, creating significant dependency and potential impact if these key relationships are terminated.
Regulatory Pricing Pressure Inflation Reduction Act and other healthcare reforms may limit partner pricing, potentially reducing future milestone and royalty revenue for the company.
Outlook
Expand Existing Partnerships Focus on identifying new opportunities with existing partners to build on trusted relationships and increase program adoption across the industry.
Increase Partner Count Continue business development to gain new customers, particularly smaller early-stage biotech companies, through flexible deal structures and expanded platform offerings.
Technological Differentiation Investment Invest in platform innovation, including AI tools and new animal technologies, to maintain competitive advantage in the antibody discovery market.
Capital Allocation Strategy Utilize existing cash of 54.0M USD to fund operations and evaluate strategic technology acquisitions to broaden antibody and target-binding discovery capabilities.
Peer Comparison
Revenue (TTM)
$70.39M
$53.43M
$36.93M
Gross Margin (Latest Quarter)
100.0%
99.9%
99.8%
Key Metrics
Symbol | Market Cap | P/E (TTM) | ROE (TTM) | Debt to Assets |
|---|---|---|---|---|
| ARMP | $310.91M | -6.6 | 70.3% | 198.5% |
| OBIO | $254.66M | -3.3 | -170.5% | 28.2% |
| CCCC | $222.81M | -2.1 | -53.8% | 16.7% |
Long-Term Trends
Last 4 Quarters
Revenue
Net Income
Operating Cash Flow
4Q Revenue CAGR
26.3%
Strong Growth
4Q Net Income CAGR
N/M
Profitability Shift
Cash Flow Stability
0%
Cash Flow Needs Attention
Deep Research
Next earnings:May 6, 2026
EPS:-
|Revenue:-
Financials
Earnings Calls
Reports
News
Income Statement
Balance Sheet
Cash Flow Statement
Ratios
% Chg.
Income Statement | LTM |
|---|
No Data